Logo

BeiGene and EUSA Receive the NMPA's Approval of Qarziba (dinutuximab beta) for High-Risk Neuroblastoma

Share this

BeiGene and EUSA Receive the NMPA's Approval of Qarziba (dinutuximab beta) for High-Risk Neuroblastoma

Shots:

  • The conditional approval is based on the SIOPEN trial evaluating dinutuximab beta vs dinutuximab beta with/out IL-2 in 514 patients aged ≥12 mos. with high-risk neuroblastoma who have received induction CT & partial response along with a history of R/R neuroblastoma with/out the residual disease. The trial was conducted by SIOPEN in collaboration with Apeiron & EUSA
  • The results also demonstrated the 5yrs. EFS rate (57% vs 42%) and OS rate (64% vs 50%). The safety of the therapy was also evaluated
  • Qarziba is a mAb targeting carbohydrate moiety of disialoganglioside 2 (GD2) & has received the EC’s approval for the same indication in 2017

  | Ref: BeiGene | Image: SybBioBeta

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions